Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Limited, an Australian biopharmaceutical company, is set to release over 800,000 shares from voluntary escrow on May 1, 2024, which were initially issued as part consideration for acquiring Lightpoint Medical’s SENSEI® radio-guided surgery business. The company specializes in the development and commercialization of radiopharmaceuticals for diagnostic and therapeutic purposes, with operations extending across the globe including the US, Europe, and Japan. Their lead imaging product, Illuccix®, has secured approvals from health authorities in the US, Australia, and Canada.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
